Four algorithms, each labelled with the stage it has actually reached. None is available for clinical use.
Full pipeline ↗[One-sentence indication to be added.] Model card in preparation.
Cardiovascular risk estimation for South Asian patients, rebuilt from SCORE2 and the HEART Score with India-specific variables.
5- and 10-year locoregional recurrence risk in non-metastatic breast cancer, re-derived for Indian patients.
Multimodal research model estimating amyloid and cognitive-decline risk in mild cognitive impairment.
AlgoMD’s Indian SaMD portfolio is not a detour from NFAD — it is the strategic architecture that makes NFAD achievable.
CDSCO Class B/C approval is faster and more accessible to a lean company than EU MDR Class IIa, making it the correct first milestone. Everything built for it — the ISO 13485 QMS, IEC 62304 lifecycle files, and clinical evaluation methodology — transfers directly to an EU MDR technical file. Each submission is a rehearsal for the Notified Body review.
Clinicians, data holders, industry, researchers and future colleagues: one form, read by the founder, answered within 48 hours.